Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.34 USD
0.00 (0.00%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $2.37 +0.03 (1.28%) 4:54 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Esperion Therapeutics, Inc. [ESPR]
Reports for Purchase
Showing records 61 - 80 ( 160 total )
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Update Provides a Peek at Key Upcoming Milestones For Bempedoic Acid Franchise
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
CLEAR Outcomes Nails It; Full Data Presentation Expected in 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
We Heart a Significant Inflection Point; CLEAR Outcomes Trial Prepping to Report Topline Data in January; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
3Q22 Results; All Eyes On CLEAR Top-Line Readout Expected in 1Q23; Pipeline Updates at Upcoming R&D Day
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Expert Panel Recommends NEXLETOL As Important Adjunctive Therapy in ASCVD; Top-Line Phase 3 Readout 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
2Q22 Results; CLEARly the Focus Is on 1Q23 as Major Inflection Point
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
1Q22 Results; Revenue Growth Continues Across U.S. and E.U. Ahead of Key Inflection Point
Provider: H.C. Wainwright & Co., Inc.
Analyst: BRANCHETTI E
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department